Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models
Paul R. Gavine(AstraZeneca (Poland)), Q. May Wang
Cited by 120
Related Papers
JNJ-79032421, a Novel Membrane-Restricted Mesothelin-Targeting T Cell–Engaging Bispecific Antibody for the Treatment of Mesothelin-Positive Cancers
|Molecular Cancer Therapeutics|2026|0